Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Basilard BioTech, Inc. logo — Nanomechanical Gene Delivery to Transform the Engineering of...

Basilard BioTech, Inc.

Nanomechanical Gene Delivery to Transform the Engineering of Cell Based Therapies

Founded 2019 United States United States 5 employees Seed Total: $250.00K Biopharma, Biotechnology +1

General Information

Company Name Basilard BioTech, Inc.
Founded Year 2019
Location United States United States
Founders / Decision Makers
Team member
Employees 5
Industries Biopharma, Biotechnology, Life Sciences
Funding Stage Seed
Revenue Model Licensing, Product Sales, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Basilard BioTech, Inc.. To contact Basilard BioTech, Inc., visit basilardbiotech.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Basilard BioTech, Inc. compare?

A PDF of Basilard BioTech, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Basilard BioTech, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Basilard BioTech, Inc.

Basilard BioTech, Inc., founded in 2019, is making strides in the Biopharma, Biotechnology, and Life Sciences industries with its innovative approach to gene delivery, addressing key impediments in the growing realm of cell-based therapies. Headquartered in the United States, the company's flagship technology, Celletto™, offers a non-viral, nanomechanical solution designed to enhance the efficacy and scalability of cell and gene therapies.

The Celletto™ platform disrupts traditional methodologies by providing a superior alternative to both biological and viral approaches in gene delivery. By utilizing mechanoporation, it offers higher transfection and viability rates compared to industry-standard electroporation and presents a scalable and cost-effective alternative for viral delivery. This technology holds particular promise in the engineering of primary T cells.

Basilard BioTech last secured seed funding on 01 February 2022 from Sunstone Management, fueling their continued innovation in this critical sector.

Business keywords: Gene Delivery Technology, Nanomechanical Transfection, Cell-Based Therapies, Non-Viral Gene Delivery, Mechanoporation, Ex-Vivo Gene Delivery, Transfection Efficiency, Cell Viability, Primary T Cell Engineering, Biotechnology Innovation, Therapeutic Scalability, Biotechnological Manufacturing Solutions, Cell and Gene Therapy Platforms, Disruptive Biotech Solutions, IP-Protected Technology

Services & Products

Gene Delivery Platform Development
Cell and Gene Therapy Solutions
Mechanoporation Technology

Target Customers

Biotechnology Companies Pharmaceutical Manufacturers Medical Researchers Healthcare Providers

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Undisclosed 1
Sunstone Management
Sunstone Management
01 Feb 2022
Seed Undisclosed 3
Casdin Capital BioBrit SeedFolio
Casdin Capital, BioBrit +1
01 Oct 2021
Seed $250.00K 1
Highlander Venture Fund
01 Feb 2020

Basilard BioTech, Inc. Alternatives & Competitors

View All Alternatives
Basilard BioTech, Inc. vs
Interius BioTherapeutics
Interius BioTherapeutics United States

Interius is developing new ways to engineer cells inside the human body, right where they live

Acquired
16 employees
Biopharma, Biotechnology
Basilard BioTech, Inc. vs
Rampart Bioscience
Rampart Bioscience United States

Leading a new era of effective, safe and accessible gene medicines.

Series A
28 employees
Biopharma, Biotechnology
Compare Basilard BioTech, Inc. vs Rampart Bioscience
Basilard BioTech, Inc. vs
Poseida Therapeutics, Inc.
Poseida Therapeutics, Inc. United States

A Member of the Roche Group

Acquired
81 employees
Biopharma, Biotechnology
Also compare with: Basilard BioTech, Inc. vs Astraveus Astraveus Basilard BioTech, Inc. vs SmartCella Holding AB SmartCella Holding AB View all alternatives

FAQ About Basilard BioTech, Inc.

Nanomechanical Gene Delivery to Transform the Engineering of Cell Based Therapies
Basilard BioTech, Inc. was founded in 2019.
Basilard BioTech, Inc. is headquartered in United States.
Basilard BioTech, Inc. operates in Biopharma, Biotechnology and Life Sciences. Its work centres on Gene Delivery Technology, Nanomechanical Transfection, Cell-Based Therapies and Non-Viral Gene Delivery. Its customers include Biotechnology Companies, Pharmaceutical Manufacturers and Medical Researchers.
Its revenue comes from Licensing, Product Sales and Service Fee.
Basilard BioTech, Inc. has approximately 5 employees.
Basilard BioTech, Inc. has completed 3 funding rounds, raising a total of $250.00K. The latest funding stage is Seed.
Basilard BioTech, Inc. offers: Gene Delivery Platform Development, Cell and Gene Therapy Solutions, Mechanoporation Technology.
Top alternatives and competitors to Basilard BioTech, Inc. include Interius BioTherapeutics, Rampart Bioscience, Poseida Therapeutics, Inc., Astraveus, SmartCella Holding AB. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Basilard BioTech, Inc. and Interius BioTherapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Basilard BioTech, Inc., https://bouncewatch.com/company/basilard-biotech-inc, updated 11 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout